Associated Genetic Biomarkers
NCI Definition: A variant of mastocytosis characterized by multifocal, dense infiltrates of mast cells (15 or more mast cells in aggregates) detected in the bone marrow and/or other extracutaneous sites. (WHO, 2001) -- 2003 
Systemic mastocytosiss most frequently harbor alterations in KIT, ASXL1, TET2, ETV6, and CDKN2A .
KIT Mutation (somatic), KIT Mutation, KIT D816V, KIT Codon 816 Missense, and ASXL1 Mutation are the most common alterations in systemic mastocytosis .
There are 3 clinical trials for systemic mastocytosis, of which 3 are open and 0 are completed or closed. Of the trials that contain systemic mastocytosis as an inclusion criterion, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 2/phase 3 (1 open).
KIT is the most frequent gene inclusion criterion for systemic mastocytosis clinical trials .
Cd16/il15/cd33 trispecific killer cell engager and flotetuzumab are the most common interventions in systemic mastocytosis clinical trials.
Significant Genes in Systemic Mastocytosis
KIT is mutated in 33.33% of systemic mastocytosis patients .
KIT is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains KIT status and systemic mastocytosis as inclusion criteria, 1 is phase 2/phase 3 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.